GRAIL Announces Novel Risk Classification Test to Be Used in Lung Cancer Study

MENLO PARK, Calif. & CAMBRIDGE, England--(BUSINESS WIRE)--GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced today that participants from Japan, via a collaboration with AstraZeneca (LSE/STO/Nasdaq:AZN), will have their samples tested using GRAIL’s novel risk classification test on its Methylation Platform. This assay has been validated for recurrence risk classification in newly diagnosed Stage I lung adenocarcinoma. GRAIL’s Methylation Platform enab ...